BFM
CRXTW

Boothbay Fund Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Boothbay Fund Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,027
Closed -$68K – 2399
2021
Q3 		$68K Sell
13,027
-2,352
-15% -$1.77K ﹤0.01% 1830
2021
Q2 		$155K Buy
+15,379
New +$9.64K 0.01% 1603

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $19.4M AUM
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Boothbay Fund Management's CRXTW Position: Q4 2021 in Review

Boothbay Fund Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q4 2021, closing a stake of 13,027 shares — an estimated $68K sold.

Boothbay Fund Management first reported a position in CRXTW in Q2 2021 and held it in 2 quarters. The position peaked at $155K in Q2 2021. 19 funds tracked by Wall St. Rank hold CRXTW as of Q4 2021.

  • Boothbay Fund Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 13,027 Clarus Therapeutics Holdings, Inc. Warrants shares in Q4 2021, an estimated $68K.
  • Boothbay Fund Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2021 and held it in 2 quarters.
  • Boothbay Fund Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $155K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.